News Agency
Men's Weekly

Alterity Therapeutics Announces Publication Demonstrating that ATH434 is Neuroprotective in Animal Model of Parkinsonian Disorder in the Journal of Parkinson's Disease

  • Written by PR Newswire

Study demonstrates reduction of α-synuclein aggregation and preservation of neurons

Alterity Therapeutics Announces Publication Demonstrating that ATH434 is Neuroprotective in Animal Model of Parkinsonian Disorder in the Journal of Parkinson's Disease

MELBOURNE, Australia, Jan. 28, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today...

Read more: Alterity Therapeutics Announces Publication Demonstrating that ATH434 is Neuroprotective in Animal...

Aligning Social, Email, and Web Campaigns with Structured Content: Building a Unified Marketing Engine

Few modern marketing campaigns exist in a bubble. A product launch, for example, may kick off with social media buzz, continue into a targeted email campaign, and finish with a conversion-focused web experience. Ideally, all three touchpoints communicate the same... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion